Analyzing biomarkers for colorectal cancer and its metastasis
A Prospective Study of Integrative Omics Analysis for Colorectal Cancer and Metastasis
This study is trying to find new markers in the blood of colorectal cancer patients with spread to help doctors personalize treatments and improve outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Academic / other |
| Locations | 1 site (Chongqing) |
| Trial ID | NCT05482529 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on understanding the mechanisms behind colorectal cancer (CRC) metastasis by collecting clinical data and specimens from patients diagnosed with CRC and confirmed distant metastasis. Using integrative omics techniques such as RNA-sequencing and ATAC-seq, the study aims to identify and predict candidate biomarkers that could enhance personalized medicine approaches. The findings are expected to deepen the understanding of CRC metastasis and aid in the development of new diagnostic and therapeutic targets, ultimately improving patient prognoses.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with colorectal adenocarcinoma who have at least one confirmed metastatic lesion.
Not a fit: Patients with recent diagnoses of other malignancies or those unable to tolerate surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate prognostic tools and targeted therapies for patients with colorectal cancer.
How similar studies have performed: Other studies utilizing integrative omics approaches have shown promise in identifying biomarkers for various cancers, suggesting potential success for this novel application in colorectal cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * colorectal adenocarcinoma by biopsy。 * at least 1 metastasis lesion comfirmed by at least 1 kind of imaging examination (CT, MRI and PET-CT ) Exclusion Criteria: * recent diagnosis with other malignancies * can not tolerate the surgery * history of serious mental illness * pregnancy or lactating women * the researchers believe the patients should not enrolled in
Where this trial is running
Chongqing
- Daping hospital — Chongqing, China (Recruiting)
Study contacts
- Study coordinator: fan li, MD
- Email: levinecq@163.com
- Phone: 86 023 68757958
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.